The MIMRYLO approval milestone and opt-out payments have transformed Protagonist into a cash-flow-positive, royalty-generating biotech. Watch for ICOTYDE royalty ramp from J&J's global launches and the pace of the $300M buyback execution. PN-881 Phase 2b initiation in early Q1 2027 is the next key pipeline catalyst.
Drugs in focus
PTGX drug pipeline →ICOTYDE
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched in the US (March 2026), EU (September 2026), and UK (October 2026).
- Next catalyst
- None dated
What to watchICOTYDE is already approved and generating revenue. The next major catalyst would be a regulatory filing for psoriatic arthritis (Phase 3 data just presented at ACR Nov 2026), but no submission or PDUFA date has been announced yet. Watch for J&J's filing plans and quarterly royalty revenue growth as the commercial launch ramps.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $132.04entry
- T+1 · 8d ago +2.92%α +0.56% · $135.90
- T+5 · 4d ago −0.83%α −3.42% · $130.95
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.07 diluted EPS) on $274.4M in license and collaboration revenue, driven by $275M in payments from Takeda triggered by FDA approval of MIMRYLO (rusfertide). Results far exceeded consensus EPS of $2.66 and revenue of $241.3M, and the company ended the quarter with $834.6M in cash and a $300M share repurchase program in place.
Key Financial Metrics
Key Facts
- FDA approval of MIMRYLO (rusfertide) triggered $275M in payments to Protagonist in Q3 2026
- Q3 2026 net income of $220.0M vs net loss of $39.3M in Q3 2025
- Diluted EPS of $3.07 vs consensus estimate of $2.66 (beat by 15.4%)
- License and collaboration revenue of $274.4M vs consensus $241.3M (beat by 13.7%)
- Cash, cash equivalents and marketable securities of $834.6M as of September 30, 2026
- $300M share repurchase program authorized in September 2026
- ICOTYDE received regulatory approvals in China, Japan and the EU during Q3 2026
- PN-881 Phase 1 study completed; Phase 2b planned for early Q1 2027
Financial Impact
Q3 2026 net income of $220.0M vs net loss of $39.3M in Q3 2025; license and collaboration revenue of $274.4M vs $4.7M in Q3 2025
Risk Factors
- Revenue is heavily dependent on milestone payments from partners (Takeda, J&J) which are lumpy and non-recurring
- ICOTYDE and MIMRYLO commercial success depends on partner execution (J&J, Takeda)
- R&D expenses expected to increase as pipeline programs advance into later-stage trials
- Share repurchase program timing and amount are discretionary
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-123351 |
| Document: tm2629043d1_8k.htm | 0001104659-26-123351 |
| Document: 0001104659-26-123351-index-headers.html | 0001104659-26-123351 |
| Document: 0001104659-26-123351-index.html | 0001104659-26-123351 |
| Document: 0001104659-26-123351.txt | 0001104659-26-123351 |
| 8-K Data (Synthetic) | 0001104659-26-123351 |
Track record
11 reports on PTGX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Viewing Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers